96 PATENT ABSTRACTS

4782018 4782026

D E T E C T I O N O F H Y D R O L Y Z I N G E N Z Y M E S

C O L L E C T I O N M E D I U M F O R W H O L E B L O O D

Jon Eikenberry, Karen L Warren, Brooke Schlegel, Dolores Humbert assigned to Eastman Kodak Company

A composition of a polysaccharide with a detec- table material appended thereto and a 1,3-dione having a methylene group between the two car- bonyls of the 1,3-dione, which methylene group has at least one ionizable hydrogen, provides ac- curate results in assays of hydrolyzing enzymes such as amylase. The composition can be in- corporated in the reagent zone of a dry test ele- ment having a reagent zone and a registration zone.

4782020

P R O C E S S F O R T H E C O N T I N U O U S E N Z Y M A T I C C O N V E R S I O N O F A L P H A -

H Y D R O C A R B O X Y L I C A C I D S I N T O T H E C O R R E S P O N D I N G O P T I C A L L Y A C T I V E A L P H A - A M I N O C A R B O X Y L I C A C I D S

Robert F Baugh, Cynthia A Taylor assigned to Hemotec Inc

An inhibitor of Platelet Factor 3 activity is in- cluded in a collection medium into which a whole blood sample is a collected. The inhibitor of Platelet Factor 3 activity, it has been discovered, prevents an initial drop in the activated clotting time measured during an assay test conducted on the whole blood sample collected in the medium. The discovery of the problem of the initial drop in the activated clotting time and the solution of including the inhibitor of Platelet Factor 3 ac- tivity is of considerable importance in heparin therapy, since the initial drop in the activated clotting time of heparinized blood is substantial. The inhibitor of Platelet Factor 3 activity can be included with a calcium chelating agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet thromboxane A2 synthesis, are effective inhibitors of Platelet Fac- tor 3 activity.

4783400

Wolfgang Leuchtenberger, Christian Wandrey, Maria-Regina Kula, Bruchk Federal Republic Of Germana assigned to Degussa Aktiengesel- lschaft

alpha-Hydroxycarboxylic acids are con- tinuously converted into the corresponding op- tically active alpha- aminocarboxylic acids. The conversion is carried out in a membrane reactor in the presence of nicotinamide-adenine dinucleotide increased in molecular weight by bonding to a water soluble high molecular weight material, a dehydrogenase specific for the alpha-hydroxycarboxylic acid, a dehydrogenase specific for the corresponding alpha-amino- carboxylic acid and ammonium ions. There is continuously supplied to the membrane reactor an aqueous solution of the alpha- hydroxycarboxylic acid to be reacted, a substan- tially lesser amount of the corresponding alpha- ketocarboxy lic acid, and an amount of ammonium ion at least equivalent to the alpha- hydroxycarboxylic acid to be reacted. There is maintained over the membrane a difference in pressure 1 and 15 bar. Behind the membrane, there is continuously drawn off a filtrate stream containing the alpha-aminocarboxylic acid for- med.

H O M O G E N E O U S E N Z Y M E I M M U N O A S S A Y S Y S T E M A N D

M E T H O D

Eleanor Canova-Davis, Viola T Kung, Carl T Redemann assigned to Cooper Lipotech

A liposome assay reagent for determination of an analyte in a homogeneous immunoassay. The reagent includes a suspension of oligolamellar lipid vesicles containing encapsulated glucose-6- phosphate dehydrogenase (G6PD), at a specific activity of between about 1-15 units/ mumole vesicle lipid, and glucose-6-phosphate (G6P) at a concentration of at least about 5 mM. The encapsulated G6P protects the enzyme against inactivation on preparation, by reverse phase evaporation in the presence of organic solvent, and on storage as an aqueous suspension.

4783401

V I A B L E C E L L L A B E L L I N G

Paul K Horan, Bruce D Jensen, Sue Slezak as- signed to SmithKline Beckman Corporation